Table 1.

Subject demographics, disposition and dose levels, mean ± SD

Group	Treatment	Gender	Number of subjects	Age (years)	Body weight (kg)	BMI (kg m−2)
A, B, C, E, F	Placebo	Male	10	33 ± 9.5	79.8 ± 12	25.7 ± 3.4
D	Placebo	Male	2	24, 48	74.1, 81.1	25.6, 26.8
H	Placebo	Female	2	61, 64	56.9, 73.0	23.4, 28.5
A	5 mg selisistat	Male	6	34 ± 13	75.7 ± 7.0	25.8 ± 2.5
B	25 mg selisistat	Male	6	39 ± 10	77.7 ± 5.6	26.8 ± 2.6
C	75 mg selisistat	Male	6	30 ± 8.7	78.5 ± 8.7	24.8 ± 2.4
D	150 mg selisistat*	Male	6	28 ± 13	84.5 ± 14	24.9 ± 3.6
E	300 mg selisistat	Male	6	32 ± 14	80.6 ± 9.7	24.5 ± 2.2
F	600 mg selisistat	Male	6	37 ± 11	84.4 ± 4.0	26.2 ± 2.4
H	300 mg selisistat	Female	6	53 ± 6.8	66.6 ± 9.1	26.1 ± 2.3
I, J, K	Placebo	Male	6	29 ± 9.9	82.7 ± 11	27.2 ± 3.2
L	Placebo	Female	2	43, 48	67.1, 74.6	24.6, 28.8
I	100 mg selisistat OD	Male	6	29 ± 8.7	79.3 ± 8.2	25.5 ± 3.7
J	300 mg selisistat OD	Male	6	28 ± 8.3	67.7 ± 5.1	21.8 ± 2.3
K	100 mg selisistat BID	Male	6	32 ± 6.2	83.6 ± 11	27.2 ± 3.0
L	100 mg selisistat BID	Female	6	48 ± 15	68.2 ± 10	24.7 ± 3.0

^*Two-period crossover in the fasted and fed states. BMI, body mass index.